Diagnosis and Management of Left Atrial Mass with Syncope
A. Diagnosis: Left Atrial Myxoma
The diagnosis is left atrial myxoma, the most common primary cardiac tumor, accounting for approximately 50% of all benign cardiac neoplasms. 1, 2
- Myxomas occur most frequently in the left atrium, typically attached to the interatrial septum 1
- They are most common in patients between the 4th and 6th decade of life, with female predominance 3
- The tumor appears as a small, circumscribed round mass on imaging (CT and echocardiography) 4, 5
- Cardiac myxomas have an incidence of 0.02% in autopsy series 1, 2
B. Mechanism of Fainting Episodes
The syncope results from mechanical obstruction of blood flow across the mitral valve during diastole, causing transient reduction in cardiac output and cerebral hypoperfusion. 1, 6, 5
Primary Mechanism: Obstructive "Ball-Valve" Effect
- The mobile tumor prollapses into the mitral valve orifice during diastole, causing dynamic flow obstruction 5, 7
- This intermittent obstruction reduces left ventricular filling and cardiac output, leading to cerebral hypoperfusion and loss of consciousness 1, 4
- Syncope is particularly common with positional changes or exertion when hemodynamic demands increase 4, 8
Additional Contributing Mechanisms
- Cardiac arrhythmias (including symptomatic bradycardia) can occur due to tumor proximity to the conduction system 5
- The tumor may cause reflex vagal responses leading to vasovagal-type syncope 6
- Larger myxomas (>6 cm) are associated with worse prognosis and more severe obstructive symptoms 3, 4
C. Microscopic Findings of Cardiac Myxoma
Cellular Components
Myxoma cells (lepidic cells):
- Polygonal to stellate-shaped cells with abundant eosinophilic cytoplasm
- Round to oval nuclei with fine chromatin
- Cells arranged singly or in small clusters within myxoid stroma 2
Stromal characteristics:
- Abundant myxoid (mucopolysaccharide-rich) extracellular matrix
- Loose, gelatinous appearance with basophilic staining
- Rich in acid mucopolysaccharides (hyaluronic acid and chondroitin sulfate)
Vascular elements:
- Thin-walled blood vessels of varying caliber
- Hemorrhage and hemosiderin deposition common
- Occasional thrombosis within tumor vessels
Additional features:
- Inflammatory cells (lymphocytes, plasma cells, macrophages) scattered throughout
- Calcification may be present, especially in older lesions
- Surface endothelial lining when attached to endocardium
- Glandular structures occasionally present (rare)
Histologic Pattern
- The cells are embedded in a loose myxoid stroma creating a characteristic "stellate" appearance
- Perivascular condensation of tumor cells is typical
- Surface may show fibrin deposition and thrombus formation (source of embolic risk) 1
Management Recommendations
Surgical excision is the definitive and only established treatment for cardiac myxoma and should be performed urgently to prevent life-threatening complications. 1, 2, 6
Surgical Indications (Class I)
- All symptomatic left atrial myxomas require surgical resection 1, 2
- Surgical excision reduces stroke risk compared to conservative management 1
- The overall embolism rate is 25% in untreated patients, with 30-40% of myxomas causing embolic events 1
Pre-operative Considerations
- Echocardiography (transthoracic and transesophageal) is the diagnostic technique of choice 2
- Cardiac MRI or CT provides additional characterization for surgical planning 2
- More villous tumor morphology indicates greater embolic potential and urgency for surgery 1
Post-operative Outcomes
- Surgical removal results in resolution of obstructive symptoms including syncope 5
- Arrhythmias (including bradycardia) typically resolve after tumor excision 5
- Prognosis is excellent with complete surgical resection 8
Critical Pitfalls to Avoid
- Do not delay surgery once diagnosis is established—risk of sudden death from complete mitral obstruction or massive embolism 4
- Do not perform pericardiocentesis if pericardial effusion is present, as this may worsen hemodynamics 1
- Avoid anticoagulation alone as definitive therapy—it does not address the mechanical obstruction and may increase bleeding risk 1